Literature DB >> 28408276

Low serum concentrations of Irisin are associated with increased risk of hip fracture in Chinese older women.

Jun Yan1, Hai-Juan Liu2, Wei-Chun Guo3, Jian Yang4.   

Abstract

OBJECTIVE: Irisin derived from muscle in response to exercise may be the molecular entity responsible for muscle wasting-osteoporosis connectivity in the elderly. The objective of the study was to determine whether serum Irisin (sIrisin) provides information on hip fracture prediction which were independent of bone mineral density (BMD) and the fracture risk assessment tool (FRAX) algorithm.
METHODS: This study enrolled 160 older women (ages, 70-90y) with minimal trauma hip fractures (MTHFs) and 160 age-matched women without fracture serving as controls. Clinical features, BMD and bone turnover markers including sIrisin levels were measured after fracture within 2 days as baseline.
RESULTS: sIrisin levels were significantly lower (361.5±140.0ng/mL vs 478.5±159.6ng/mL, P<0.001) in cases than controls. After multivariate analysis, sIrisin remained as an independent variable of BMD, which explained 17.8% of femoral neck BMD and 22.5% of lumbar spine BMD, respectively. The odds ratio (OR) of MTHFs comparing the lowest (<320.1ng/mL) to highest (>524.5ng/mL) quartiles was 1.95 (95% CI 1.23-3.79, P<0.05) for sIrisin. Adjustment for age, body mass index, time since menopause and exercise ≥30min/day yielded similar results, and BMD of femoral neck also did not change these associations. Taking FRAX score into account attenuated the association somewhat: OR of hip fracture was 1.81 (95% CI 1.26-3.49, P<0.05) in first versus fourth quartile of sIrisin. There was a negative gradient of risk by decreasing quartile in sIrisin.
CONCLUSIONS: Low concentrations of sIrisin in older women were independently associated with increased risk of hip fractures when adjusted for BMD or FRAX score.
Copyright © 2017. Published by Elsevier SAS.

Entities:  

Keywords:  Bone mineral density; Elderly; Hip fracture; Irisin; Osteoporosis

Mesh:

Substances:

Year:  2017        PMID: 28408276     DOI: 10.1016/j.jbspin.2017.03.011

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  13 in total

Review 1.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

Review 2.  Physical Activity and Post-Transcriptional Regulation of Aging Decay: Modulation of Pathways in Postmenopausal Osteoporosis.

Authors:  Federica Vita; Sebastiano Gangemi; Giovanni Pioggia; Fabio Trimarchi; Debora Di Mauro
Journal:  Medicina (Kaunas)       Date:  2022-06-06       Impact factor: 2.948

Review 3.  Role of the Myokine Irisin on Bone Homeostasis: Review of the Current Evidence.

Authors:  Amanda Kornel; Danja J Den Hartogh; Panagiota Klentrou; Evangelia Tsiani
Journal:  Int J Mol Sci       Date:  2021-08-24       Impact factor: 6.208

4.  Decreased Concentration of Irisin Is Associated with Poor Functional Outcome in Ischemic Stroke.

Authors:  Wen-Jun Tu; Han-Cheng Qiu; Jian-Lei Cao; Qiang Liu; Xian-Wei Zeng; Ji-Zong Zhao
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

5.  Irisin deficiency disturbs bone metabolism.

Authors:  Xiaofang Zhu; Xiangfen Li; Xiaoxuan Wang; Ting Chen; Fengjuan Tao; Chuanju Liu; Qisheng Tu; Guofang Shen; Jake J Chen
Journal:  J Cell Physiol       Date:  2020-06-22       Impact factor: 6.384

6.  Delivery vehicle of muscle-derived irisin based on silk/calcium silicate/sodium alginate composite scaffold for bone regeneration.

Authors:  Xianzhen Xin; Jiannan Wu; Ao Zheng; Delong Jiao; Yang Liu; Lingyan Cao; Xinquan Jiang
Journal:  Int J Nanomedicine       Date:  2019-02-22

Review 7.  Bone and Muscle Crosstalk in Aging.

Authors:  Chen He; Wenzhen He; Jing Hou; Kaixuan Chen; Mei Huang; Mi Yang; Xianghang Luo; Changjun Li
Journal:  Front Cell Dev Biol       Date:  2020-12-10

8.  The Association of Serum Irisin with Bone Mineral Density and Turnover Markers in New-Onset Type 2 Diabetic Patients.

Authors:  Xiujing Wang; Tianxiao Hu; Yun Ruan; Jiaqi Yao; Huiling Shen; Yao Xu; Bojing Zheng; Zhengying Zhang; Jing Wang; Qingying Tan
Journal:  Int J Endocrinol       Date:  2022-02-28       Impact factor: 2.803

9.  The Irisin Hormone Profile and Expression in Human Bone Tissue in the Bone Healing Process in Patients.

Authors:  Sancar Serbest; Uğur Tiftikçi; Hacı Bayram Tosun; Üçler Kısa
Journal:  Med Sci Monit       Date:  2017-09-04

Review 10.  Irisin and Secondary Osteoporosis in Humans.

Authors:  Roberta Zerlotin; Angela Oranger; Patrizia Pignataro; Manuela Dicarlo; Filippo Maselli; Giorgio Mori; Silvia Concetta Colucci; Maria Grano; Graziana Colaianni
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.